Curative therapies for hepatocellular carcinoma: An update and perspectives

Expert Review of Anticancer Therapy

Volumn 16, Issue 2, 2016, Pages 169-175

  Sacco, Rodolfo ^a   Antonucci, Michela ^b   Bresci, Giampaolo ^a   Corti, Ambra ^c   Giacomelli, Luca ^d   Mismas, Valeria ^a   Rainieri, Maurizio ^b   Romano, Antonio ^a   Eggenhoffner, Roberto ^d   Tumino, Emanuele ^a   Cabibbo, Giuseppe ^b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Free Researcher   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Ablative therapy; early stage; HCC; liver transplant; PEI; resection; RFA

Indexed keywords

CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LAPAROSCOPIC SURGERY; LASER SURGERY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MICROWAVE THERAPY; POSTOPERATIVE COMPLICATION; RADIOFREQUENCY ABLATION; RECURRENCE RISK; REVIEW; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ABLATION THERAPY; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; LIVER RESECTION; PATHOLOGY; PROCEDURES;

ABLATION TECHNIQUES; CARCINOMA, HEPATOCELLULAR; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION;

EID: 84957433160     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2016.1123625     Document Type: Review

References (63)

1. Cabibbo G, Maida M, Genco C., et al. Causes of and prevention strategies for hepatocellular carcinoma. Semin Oncol. 2012; 39: 374-383.
2. Cammà C, Cabibbo G. Prognostic scores for hepatocellular carcinoma: none is the winner. Liver Int. 2009; 29: 478-480.
3. Akoad ME, Pomfret EA. Surgical resection and liver transplantation for hepatocellular carcinoma. Clin Liver Dis. 2015; 19: 381-399.
4. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56: 908-943.
5. Munene G, Vauthey JN, Dixon E. Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC. Int J Hepatol. 2011; 2011: 565060.
6. Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol. 2015; 7: 673-687.
7. Lee KK, Kim DG, Moon IS., et al. Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol. 2010; 101: 47-53.
8. Ishizawa T, Hasegawa K, Aoki T., et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008; 134: 1908-1916.
9. Cucchetti A, Ercolani G, Vivarelli M., et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg. 2008; 250: 922-928.
10. Schlachterman A, Craft WW Jr, Hilgenfeldt E., et al. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol. 2015; 21: 8478-8491.
11. Kinoshita H, Sakai K, Hirohashi K., et al. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg. 1986; 10: 803-808.
12. Li N, Wu YR, Wu B., et al. Surgical and oncologic outcomes following laparoscopic versus open liver resection for hepatocellular carcinoma: A meta-analysis. Hepatol Res. 2012; 42: 51-59.
13. Morise Z, Kawabe N, Tomishige H., et al. Recent advances in liver resection for hepatocellular carcinoma. Front Surg. 2014; 1: 21.
14. Roayaie S, Obeidat K, Sposito C., et al. Resection of hepatocellular cancer.2 cm: results from two Western centers. Hepatology. 2013; 57: 1426-1435.
15. Nault JC, De Reyniès A, Villanueva A., et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013; 145: 176-177.
16. Minagawa M, Makuuchi M, Takayama T., et al. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003; 238: 703-710.
17. Yang T, Lin C, Zhai J., et al. Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging. J Cancer Res Clin. 2012; 138: 1121-1129.
18. Mazzaferro V, Chun YS, Poon RT., et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008; 15: 1001-1007.
19. De Lope CR, Tremosini S, Forner A., et al. Management of HCC. J Hepatol. 2012; 56 (Suppl 1): S75-87.
20. Mazzaferro V, Llovet JM, Miceli R., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009; 10: 35-43.
21. Mazzaferro V, Bhoori S, Sposito C., et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011; 17 (Suppl 2): S44-57.
22. Guglielmi A, Ruzzenente A, Conci S., et al. Hepatocellular carcinoma: surgical perspectives beyond the Barcelona clinic liver cancer recommendations. World J Gastroenterol. 2014; 20: 7525-7533.
23. Grant RC, Sandhu L, Dixon PR., et al. Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Transplant. 2013; 27: 140-147.
24. Liang W, Wu L, Ling X., et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2012 Oct; 18 (10): 1226-1236.
25. Schwartz M, Dvorchik I, Roayaie S., et al. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol. 2009; 49: 581-588.
26. Duvoux C, Roudot-Thoraval F, Decaens T., et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012; 143: 986-994.
27. Toso C, Asthana S, Bigam DL., et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009; 49: 832-838.
28. Sacco R, Gadaleta-Caldarola G, Galati G., et al. EASL HCC summit: liver cancer management. Future Oncol. 2014; 10: 1129-1132.
29. Cabibbo G, Maida M, Genco C., et al. Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. PLoS One. 2013; 8: e70016.
30. Latteri F, Sandonato L, Di Marco V., et al. Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. Dig Liver Dis. 2008; 40: 684-689.
31. Kim YS, Lim HK, Rhim H., et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013; 58: 89-97.
32. Cabibbo G, Antonucci M, Sacco R., et al. Ultrasound-guided ablation for hepatocellular carcinoma: time for a reappraisal? Exp Rev Anticancer Ther. 2015; 15: 147-150.
33. Germani G, Pleguezuelo M, Gurusamy K., et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. J Hepatol. 2013; 52: 380-388.
34. Oeda S, Mizuta T, Isoda H., et al. Survival advantage of radiofrequency ablation for hepatocellular carcinoma: comparison with ethanol injection. Hepatogastroenterology. 2013; 60: 1399-1404.
35. Shen A, Zhang H, Tang C., et al. Systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. J Gastroenterol Hepatol. 2013; 28: 793-800.
36. Giorgio A, Di Sarno A, De Stefano G., et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res. 2011; 31: 2291-2295.
37. Cucchetti A, Piscaglia F, Cescon M., et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol. 2013; 59: 300-307.
38. Yang B, Zan RY, Wang SY., et al. Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. World J Surg Oncol. 2015; 13: 96.
39. Forner A, Bruix J. Ablation for hepatocellular carcinoma: is there need to have a winning technique? J Hepatol. 2010; 52: 310-312.
40. Fu C, Liu N, Deng Q., et al. Radiofrequency ablation vs. surgical resection on the treatment of patients with small hepatocellular carcinoma: a system review and meta-analysis of five randomized controlled trials. Hepatogastroenterology. 2014; 61: 1722-1729.
41. Huang J, Yan L, Wu H., et al. Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation? J Surg Res. 2015. [. Epub ahead of print].
42. Lei JY, Wang WT, Yan LN., et al. Radiofrequency ablation versus surgical resection for small unifocal hepatocellular carcinomas. Medicine (Baltimore). 2014; 93: e271.
43. Kim JM, Kang TW, Kwon CH., et al. Single hepatocellular carcinoma ≤3 cm in left lateral segment: liver resection or radiofrequency ablation? World J Gastroenterol. 2014; 20: 4059-4065.
44. Gory I, Fink M, Bell S., et al. Melbourne Liver Group. Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study. Scand J Gastroenterol. 2015; 50: 567-576.
45. Spolverato G, Vitale A, Ejaz A., et al. The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. World J Surg. 2015; 39: 1474-1484.
46. Peng ZW, Zhang YJ, Chen MS., et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013; 31: 426-432.
47. Thandassery RB, Goenka U, Goenka MK. Role of local ablative therapy for hepatocellular carcinoma. J Clin Exp Hepatol. 2014; 4 (Suppl 3): S104-111.
48. Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 2015; 7: 1632-1651.
49. Wang C, Wang H, Yang W., et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015; 61: 1579-1590.
50. Poon RT, Fan ST, Tsang FH., et al. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeons perspective. Ann Surg. 2002; 235: 466-486.
51. Zhu H, Zhou K, Zhang L., et al. High intensity focused ultrasound (HIFU) therapy for local treatment of hepatocellular carcinoma: role of partial rib resection. Eur J Radiol. 2009; 72: 160-166.
52. Sugimoto K, Moriyasu F, Kobayashi Y., et al. Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan. Jpn J Radiol. 2015; 33: 424-432.
53. Niessen C, Igl J, Pregler B., et al. Factors associated with short-term local recurrence of liver cancer after percutaneous ablation using irreversible electroporation: a prospective single-center study. J Vasc Interv Radiol. 2015; 26: 694-702.
54. Cheung W, Kavnoudias H, Roberts S., et al. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. Technol Cancer Res Treat. 2013; 12: 233-241.
55. Mazzola A, Costantino A, Petta S., et al. Recurrence of hepatocellular carcinoma after liver transplantation: an update. Future Oncol. 2015;11:2923-2936.
56. Sacco R, Gadaleta-Caldarola G, Galati G., et al. European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers? Future Oncol. 2014; 10: 1719-1721.
57. Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma. Gut Liver. 2015; 9: 267-317.
58. Cillo U, Burra P, Mazzaferro V., et al. I-BELT (Italian board of experts in the field of liver transplantation). A multistep, consensus-based approach to organ allocation in liver transplantation: toward a "Blended Principle Model". Am J Transplant. 2015;15:2552-2561.
59. Bruix J, Takayama T, Mazzaferro V., et al. STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015; 16: 1344-1354.
60. Xu J, Li J, Chen J., et al. Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy: meta-analysis. Adv Clin Exp Med. 2015; 24: 331-340.
61. Ishikawa T. Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2013; 19: 8861-8866.
62. Cabibbo G, Enea M, Attanasio M., et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010; 51: 1274-1283.
63. Villa E, Critelli R, Lei B., et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut. 2015. [. Epub ahead of print].